News
Article
WuXi Manufacturing Facility Passes FDA Inspection
Author(s):
WuXi PharmaTech completed a general GMP and pre-approval inspection from FDA.
The CRO/CMO WuXi PharmaTech, reports that its that its small-molecule API and advanced intermediate manufacturing facility of WuXi’s wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) completed a general GMP and pre-approval inspection from FDA with no Form 483 issued.
Source: WuXi PharmaTech
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Videos
Related Content
